CLINICAL TRIALS PROFILE FOR ARISTADA
✉ Email this page to a colleague
All Clinical Trials for aristada
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01469039 ↗ | A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia | Completed | Alkermes, Inc. | Phase 3 | 2011-12-01 | The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation. |
| NCT02634320 ↗ | A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia | Completed | Alkermes, Inc. | Phase 4 | 2015-12-01 | This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070). |
| NCT03345979 ↗ | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | Completed | Alkermes, Inc. | Phase 3 | 2017-11-15 | This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL. |
| NCT04203056 ↗ | Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | Recruiting | Alkermes, Inc. | Phase 4 | 2019-12-16 | This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for aristada
Condition Name
Clinical Trial Locations for aristada
Trials by Country
Clinical Trial Progress for aristada
Clinical Trial Phase
Clinical Trial Sponsors for aristada
Sponsor Name
